TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ESSA Pharma ( (EPIX) ) has issued an update.
On October 9, 2025, ESSA Pharma Inc. announced the completion of its acquisition by XenoTherapeutics, a Massachusetts-based research foundation focused on xenotransplantation. The acquisition involved Xeno acquiring all outstanding common shares of ESSA, with a contingent value right tied to potential future payments. Following the acquisition, ESSA plans to delist from Nasdaq and terminate its registration under the U.S. Securities Exchange Act. The acquisition was approved by the Supreme Court of British Columbia on October 7, 2025.
The most recent analyst rating on (EPIX) stock is a Hold with a $2.25 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Average Trading Volume: 6,752,075
Technical Sentiment Signal: Sell
Current Market Cap: $9.7M
For detailed information about EPIX stock, go to TipRanks’ Stock Analysis page.